Pulmonary disease following intravesical BCG treatment.
Open Access
- 1 September 1990
- Vol. 45 (9), 709-710
- https://doi.org/10.1136/thx.45.9.709
Abstract
Bacillus Calmette-Guérin (BCG) is an attenuated strain of Mycobacterium bovis that has been used in the treatment of malignant disease for over 20 years and for the treatment of bladder cancer since 1976. Major complications of this treatment are infrequent. We report two cases of systemic illness with pulmonary manifestations after treatment with intravesical BCG.This publication has 6 references indexed in Scilit:
- Pulmonary complications of intravesical Bacille Calmette-Guérin immunotherapy.Published by Elsevier ,1987
- Complications of Bacillus Calmette-Guerin Immunotherapy in 1,278 Patients with Bladder CancerJournal of Urology, 1986
- SYSTEMIC COMPLICATIONS OF INTRAVESICAL BCG THERAPY FOR BLADDER CANCERThe Lancet, 1985
- Bacillus Calmette-Guerin Immunotherapy for Bladder CancerJournal of Urology, 1985
- Experience with Bacillus Calmette-Guerin in Patients with Superficial Bladder CarcinomaJournal of Urology, 1982
- Intracavitary Bacillus Calmette-guerin in the Treatment of Superficial Bladder TumorsJournal of Urology, 1976